Nurix Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 284
- Market Cap
- $1.5B
- Website
- http://www.nurixtx.com
- Introduction
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Relative Bioavailability of NX-5948 Tablets Vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06717269
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06691828
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: IPDrug: Matching Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06593457
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Conditions
- Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Diffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Waldenstrom Macroglobulinemia (WM)Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 572
- Registration Number
- NCT05131022
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele, Milano, Italy
🇨🇭University Hospital Zurich, Zürich, Switzerland
🇬🇧The Beatson WOS Cancer Center, Glasgow, Scotland, United Kingdom
A Study of DeTIL-0255 in Adults With Advanced Malignancies
- Conditions
- Endometrial CancerCervical CancerPlatinum-resistant Ovarian Cancer
- Interventions
- Biological: Drug Product De-TIL-0255
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05107739
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
A Study of NX-1607 in Adults With Advanced Malignancies
- Conditions
- Gastric CancerMetastatic Urothelial CarcinomaCervical CancerRichter TransformationOvarian Cancer, EpithelialNon-small Cell Lung Cancer (NSCLC)Microsatellite Stable Colorectal CarcinomaGastroEsophageal Junction (GEJ) CancerHead and Neck Squamous Cell CarcinomaMetastatic or Unresectable Melanoma
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 345
- Registration Number
- NCT05107674
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Colorado School of Medicine, Aurora, Colorado, United States
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Conditions
- Small Lymphocytic Lymphoma (SLL)Follicular Lymphoma (FL)Chronic Lymphocytic Leukemia (CLL)Waldenstrom Macroglobulinemia (WM)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Diffuse Large B-cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)
- Interventions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 266
- Registration Number
- NCT04830137
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California Irvine, Orange, California, United States